Gain Therapeutics, Inc. GANX
1.05 USD -0.06 (-5.41%)
Regular-session close
1.07 +0.02 +1.90%
After hours · Nov 19, 6:59 PM ET
1.03 Day range 1.14
0.94 52-week range 4.34
- YTD
- -67.39%
- 1 year
- -61.82%
News
globenewswire.com Gain Therapeutics Presents Clinical Data from Phase 1b Study of Rexaceract and Preclinical Data from Novel GCase Modulator GT-04686 IAPRD late-breaking poster shows MDS-UPDRS motor scores remained stable compared to baseline recorded at study entry with no disease progression among the 13 evaluable participants who completed 12…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers SELLAS Life Sciences Gr (NASDAQ:SLS) shares rose 169.8% to $20.16 during Tuesday's regular session. The market value of their outstanding shares is at $1.5 billion. As per the press release,…
zacks.com Gain Therapeutics (GANX) Upgraded to Buy: Here's What You Should Know Gain Therapeutics (GANX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).benzinga.com Gain Therapeutics Q3 EPS $(0.07) Beats $(0.12) Estimate Gain Therapeutics (NASDAQ:GANX) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.12) by 41.67 percent. This is a 53.33 percent increase over losses of…
globenewswire.com Gain Therapeutics Reports Financial Results for Third Quarter 2026 and Provides Corporate Update BETHESDA, Md., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the…
globenewswire.com Gain Therapeutics Announces Late-Breakers and Poster Presentations at Upcoming Scientific Conferences BETHESDA, Md., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the…
globenewswire.com Sibylla Biotech Appoints Usman Azam CEO, Gianluca Fuggetta CFO, and Expands Executive Team to Drive Transition to Clinic Milan, Italy, October 13, 2026 – Sibylla Biotech today announced key executive appointments, including Usman Azam, MD, as Chief Executive Officer and Gianluca Fuggetta, MSc, MBA, as Chief Financial…
globenewswire.com Gain Therapeutics to Attend the 2026 Maxim Growth Summit BETHESDA, Md., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the…
globenewswire.com Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration MDS-UPDRS motor scores demonstrated stability to baseline recorded at study entry with no disease progression among the 12 evaluable participants who completed 12 months of daily oral administration…
globenewswire.com Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson's Disease and Movement Disorders BETHESDA, Md., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of…
defenseworld.net Gain Therapeutics (NASDAQ:GANX) versus Spyre Therapeutics (NASDAQ:SYRE) Head to Head Comparison Spyre Therapeutics (NASDAQ: SYRE - Get Free Report) and Gain Therapeutics (NASDAQ: GANX - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two…
globenewswire.com Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference BETHESDA, Md., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain” or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the…
globenewswire.com Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference BETHESDA, Md., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain” or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the…
globenewswire.com Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update BETHESDA, Md., July 16, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the…
globenewswire.com Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson's Disease IND authorization paves the way for initiation of GT-02287 Phase 2 clinical development in the U.S., expected during 3Q26
globenewswire.com Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit BETHESDA, Md., June 10, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the…
globenewswire.com Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026 MDS-UPDRS scores remained stable and durable across overall study population after 150 days of treatment with GT-02287 Differential response between participants with low and high baseline GluSph…
globenewswire.com Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update BETHESDA, Md., May 11, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the…
globenewswire.com Gain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026 BETHESDA, Md., April 24, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of…
globenewswire.com Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update BETHESDA, Md., March 26, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of…
defenseworld.net Gain Therapeutics Highlights GT-02287 Biomarker Signals, Eyes Phase 2 Start in Q3 at Roth Conference Gain Therapeutics (NASDAQ: GANX) is developing oral small-molecule drugs aimed at neurodegenerative diseases, with its lead focus on Parkinson's disease, company CEO Gene Mack said during a fireside…
globenewswire.com Gain Therapeutics to Present at the 38th Annual ROTH Conference BETHESDA, Md., March 19, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of…
